Wegovy side effects: what hospitalisation stories leave out

What did @sarahjaynecullen actually say?

Honestly? Almost nothing medically useful. The transcript is song lyrics, not a personal account of what sent her to the hospital. The caption does the heavy lifting here, implying she ended up hospitalized after starting Wegovy despite going to "the right prescriber." The actual spoken content doesn't support or contradict anything, because it isn't a health claim at all.

This matters because 339,000+ viewers are likely watching a woman in what appears to be a hospital setting, processing the caption's implication that Wegovy caused a serious medical episode. That framing carries real weight even when the words on screen are a pop song. The caption phrases like "never once thought I would end up in this situation" do the persuasive work, suggesting a cautionary tale about GLP-1 medications, without actually making a falsifiable statement.

Does the science back up the implied claim that Wegovy causes hospitalizations?

GLP-1 receptor agonists do carry real, documented risks, and hospitalizations do happen. But context is everything. The rate of serious adverse events in clinical trials is low, and hospitalizations from semaglutide are typically tied to specific, known mechanisms.

The SELECT trial (Lincoff et al., 2023, NEJM) followed over 17,000 participants and found semaglutide significantly reduced major cardiovascular events, but it also documented adverse events including gastrointestinal complications serious enough to cause discontinuation in roughly 16% of participants. Pancreatitis, while rare, is a labeled risk. Severe gastroparesis, sometimes called "stomach paralysis," has been reported in post-marketing case series (Sodhi et al., 2023, JAMA), with researchers finding GLP-1 agonist users had significantly higher rates of gastroparesis diagnosis compared to users of bupropion-naltrexone. Biliary disease, including gallstones requiring hospitalization, is another documented risk elevated in rapid weight loss contexts.

None of this means Wegovy is uniquely dangerous. It means the risks are real, specific, and worth knowing before you start.

What did she get wrong, or right?

There is nothing to fact-check in the spoken words because she spoke song lyrics. That is not a criticism of her experience, which may have been genuinely serious and scary. But it means this video functions as pure emotional narrative, not information.

What the caption implies, that doing everything right (good prescriber, following the stories, managing expectations) still didn't protect her, is actually a fair and honest point. Adverse events don't only happen to people who took shortcuts or ignored warnings. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide's efficacy clearly, but serious adverse events occurred in 6.8% of the semaglutide group versus 5% on placebo. Even in controlled, well-monitored trials, people end up in bad situations.

Where the video fails its audience is in leaving the cause completely unaddressed. Was it dehydration from nausea and vomiting? Pancreatitis? Gallstones? An unrelated event that happened to coincide with starting Wegovy? Without that, viewers are left to project their fears onto a blank screen.

What should you actually know before starting or continuing a GLP-1 medication?

The documented side effect profile for semaglutide is not a rumor. Nausea, vomiting, and diarrhea are the most common issues, affecting up to 44% of users in the STEP trials. These are usually manageable but can lead to dehydration serious enough to require IV fluids. That is not a rare edge case. It is a known, expected pattern, especially in the first weeks after a dose increase.

Specific warning signs that warrant urgent medical attention include:

• Severe, persistent abdominal pain that may radiate to the back (possible pancreatitis)
• Signs of dehydration: dizziness, rapid heartbeat, inability to keep fluids down
• Symptoms of gallbladder disease: pain in the upper right abdomen, fever, jaundice
• Significant worsening of pre-existing gastroparesis symptoms

Going to "the right prescriber" reduces risk but does not eliminate it. A good prescriber will titrate slowly, monitor labs, and give you a clear protocol for when to call or go to an ER. If you were not given that protocol, that is worth raising before your next dose.

The bigger picture: viral hospital content and GLP-1 fear

TikTok has become one of the primary ways people form expectations about weight loss medications, and the emotional impact of a hospital-setting video is enormous regardless of what words are spoken. Research on health misinformation spread (Sharma et al., 2019, NPJ Digital Medicine) found that emotional resonance, not accuracy, drives health content sharing.

This video is not misinformation in the traditional sense. It does not make false claims. But it frames a lived experience in a way that implies cause and effect without establishing it, and it reaches hundreds of thousands of people at the exact moment they are deciding whether to try or continue a medication. That carries responsibility, even unintentionally. If you are weighing GLP-1 therapy, your starting point should be peer-reviewed data and a conversation with a licensed clinician, not a caption and a song.